EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access

High‐Intensity Statin Reduces the Risk of Mortality Among Chronic Liver Disease Patients With Atherosclerotic Cardiovascular Disease: A Population‐Based Cohort Study

Sungho Bea iD, In-Sun Oh iD, Ju Hwan Kim iD, Dong Hyun Sinn, Yoosoo Chang iD, Seungho Ryu iD, Ju-Young Shin iD

Journal of the American Heart Association · 2023

DOI: 10.1161/jaha.122.028310 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Journal of the American Heart Association, 2023. Verfasst von Sungho Bea und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy Sungkyunkwan University Suwon South Korea. Hauptthemen laut MEDLINE: Hydroxymethylglutaryl-CoA Reductase Inhibitors, Cardiovascular Diseases, Atherosclerosis, Myocardial Infarction. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

2018 American Heart Association/American College of Cardiology cholesterol guideline recommends statin in patients with chronic and/or stable liver disease for secondary prevention of atherosclerotic cardiovascular disease yet remains equivocal on the adequate intensity of statin for patients with chronic liver disease (CLD). We aimed to assess the association between statin intensity and mortality among patients with CLD with atherosclerotic cardiovascular disease. Methods and Results We conducted a population‐based cohort study in South Korea. We assessed the risk of survival and clinical outcomes using inverse probability of treatment‐weighted Cox proportional hazards regression. We also estimated the absolute risk difference between treatment groups based on the Poisson distribution. During an average of 2.35 person‐years, 10 442 patients with CLD with atherosclerotic cardiovascular disease were identified. Among those patients, 5515 (52.8%) received high‐intensity statin, and 4927 (47.2%) received low/moderate‐intensity statin. High‐intensity statin was associated with lower risk for all‐cause mortality (hazard ratio [HR], 0.83 [95% CI, 0.75–0.92]), cardiovascular‐cause mortality (HR, 0.85 [0.71–1.01]), liver‐cause mortality (HR, 0.72 [0.54–0.97]) compared with low/moderate‐intensity statin. Although both hospitalizations for recurrent myocardial infarction and stroke were shown to be increased among high‐intensity statin users, effect estimate was homogeneous in the absolute scale (myocardial infarction: HR, 1.12 [1.04–1.19], risk difference, 7.57 [−0.69 to 15.84] per 1000 person‐years; stroke: HR, 1.11 [0.97 to 1.27]; risk difference, −1.70 [−5.19 to 1.78]).

Conclusions

Among patients with CLD with atherosclerotic cardiovascular disease, high‐intensity statin was significantly associated with a lower risk of mortality. These findings herein support the guidelines for statin use in patients with CLD while demonstrating potential benefit of optimal intensity use.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hydroxymethylglutaryl-CoA Reductase InhibitorsCardiovascular DiseasesAtherosclerosisMyocardial InfarctionStrokeLiver DiseasesHumansCohort Studies

Stichwörter der Autor:innen

atherosclerotic cardiovascular diseasechronic liver diseaseepidemiologypreventionstatin intensity

Substanzen

Hydroxymethylglutaryl-CoA Reductase Inhibitors

Autor:innen und Institutionen

  • School of Pharmacy Sungkyunkwan University Suwon South Korea.
  • Department of Epidemiology, Biostatistics, and Occupational Health McGill University Montreal Quebec Canada.
  • Centre for Clinical Epidemiology Lady Davis Research Institute, Jewish General Hospital Montreal Quebec Canada.
  • Department of Biohealth Regulatory Science Sungkyunkwan University Suwon South Korea.
  • Division of Gastroenterology, Department of Medicine, Samsung Medical Center Sungkyunkwan University School of Medicine Seoul South Korea.
  • Center for Cohort Studies, Total Healthcare Center, Kangbuk Samsung Hospital Sungkyunkwan University School of Medicine Seoul Republic of Korea.

ORCID-Profile: Sungho Bea, In-Sun Oh, Ju Hwan Kim, Yoosoo Chang, Seungho Ryu, Ju-Young Shin

Zitieren

APA

Bea, S., Oh, I. S., Kim, J. H., Sinn, D. H., Chang, Y., Ryu, S., & Shin, J. Y. (2023). High‐Intensity Statin Reduces the Risk of Mortality Among Chronic Liver Disease Patients With Atherosclerotic Cardiovascular Disease: A Population‐Based Cohort Study. Journal of the American Heart Association. https://doi.org/10.1161/jaha.122.028310

Vancouver

Bea S, Oh IS, Kim JH, Sinn DH, Chang Y, Ryu S, et al. High‐Intensity Statin Reduces the Risk of Mortality Among Chronic Liver Disease Patients With Atherosclerotic Cardiovascular Disease: A Population‐Based Cohort Study. Journal of the American Heart Association. 2023. doi:10.1161/jaha.122.028310

BibTeX
@article{Bea2023,
  author = {Bea, Sungho and Oh, In-Sun and Kim, Ju Hwan and Sinn, Dong Hyun and Chang, Yoosoo and Ryu, Seungho and Shin, Ju-Young},
  title = {High‐Intensity Statin Reduces the Risk of Mortality Among Chronic Liver Disease Patients With Atherosclerotic Cardiovascular Disease: A Population‐Based Cohort Study},
  journal = {Journal of the American Heart Association},
  year = {2023},
  doi = {10.1161/jaha.122.028310}
}
Kostenlos starten →